Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Brought to you by

AstraZeneca licenses ISIS-STAT3 and other antisense projects from Isis; deal expanded to include new therapy areas

01 Dec 2020

Executive Summary

One day after announcing a tie-up with long-time partner Biogen Idec, Isis Pharmaceuticals Inc. signed a deal with AstraZeneca PLC for the development of antisense therapeutics against five cancer targets.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By